<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02528448</url>
  </required_header>
  <id_info>
    <org_study_id>NPE-01-2014</org_study_id>
    <nct_id>NCT02528448</nct_id>
  </id_info>
  <brief_title>0,9% NaCl Effect on Kidney Function and Glycocalyx in Patients Operated on for Primary Hiparthrosis</brief_title>
  <acronym>KIPA</acronym>
  <official_title>The Effect of 0,9% NaCl on the Kidney Function, Vasoactive Hormones, Biomarkers and Glycosaminglycanes in Plasma in Patients Operated on for Primary Hiparthrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regional Hospital Holstebro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regional Hospital Holstebro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if chloride is nephrotoxic using 0,9% saline versus
      Plasma-Lytein in patients having primary hip replacement surgery. The outcome is found
      measuring bio markers, vasoactive hormones and salt regulation. And to measure syndecan as a
      marker for glycocalyx degradation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis:

      Chloride has a nephrotoxic effect, which can be shown partially by measuring bio markers for
      tubular injury in urine, partially by the changes in tubular transport of sodium and water in
      different parts of the nephron. This can be demonstrated using isotone sodium solutions with
      a lower chloride concentration in this study plasma-lyte versus normal isotone saline.

      Klorid has a toxic effect on the glycocalyx layer and leads to a rise in syndecan 1 and
      simultaneously a change in Salt Blood Test either by a direct simulation and ANP levels in
      plasma or as a consequence of the hyperchloremic acidosis. This can be demonstrated using
      isotone sodium solutions with a lower chloride concentration in this study plasma-lyte versus
      normal isotone saline.

      Purpose:

      The purpose is to observe changes in bio markers, vasoactive hormones and salt regulation in
      patients randomized to either 0,9% saline or plasma-lyte undergoing primary uncemented hip
      replacement surgery.

      Design:

      40 patients undergoing primary uncemented hip replacement surgery will be randomized to
      either 0,9% saline or plasma-lyte for standard fluid resuscitation and blood loss replacement
      in this controlled and double blinded study. The patients will deliver a 24 hour urine sample
      before surgery and approximately 10 days after. From the start of the surgery and to the day
      after all urine will be collected and blood samples will be taken.

      Perspective:

      If chloride is found to be nephrotoxic it could lead to a general change in fluid
      resuscitation recommendations in critically ill patient, patients with kidney disease and
      patients undergoing surgery. It will also expand our knowledge about the permeability of the
      blood vessels.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary excretion of Neutrophil gelatinase-associated lipocalin</measure>
    <time_frame>two days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma Syndecan-1</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma renin concentration</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of cyclic guanosine monophosphate</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of epithelial sodium channels</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of water channels</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of angiotensin 2</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of aldosterone</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of atrial natriuretic peptide (ANP)</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of brain natriuretic peptide (BNP)</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of cyclic guanosine monophosphate (cGMP)</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of endothelin</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of vasopressin (AVP, ADH)</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of Fatty acid-binding protein</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of Kidney Injury Molecule</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free water clearance</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of albumin</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of chloride</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of creatinine</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma osmolarity</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of sodium</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of potassium</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of creatinine</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of chloride</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of sodium</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of potassium</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional urinary sodium excretion</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary osmolarity</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of albumin</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of sodium-chloride symporter</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pH</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulse</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>middle arterial pressure</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Nephrotoxicity</condition>
  <arm_group>
    <arm_group_label>plasma-lyte</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous 1 hour infusion of plasma-lyte 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0,9% saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous 1 hour infusion of 0,9% saline15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plasma-lyte</intervention_name>
    <description>Continuous 1 hour infusion of plasma-lyte 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement</description>
    <arm_group_label>plasma-lyte</arm_group_label>
    <other_name>ATC: B 05 BB 01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0,9% saline</intervention_name>
    <description>Continuous 1 hour infusion of 0,9% saline 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement</description>
    <arm_group_label>0,9% saline</arm_group_label>
    <other_name>sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication for uncemented primary hiparthroplasty

          -  age &lt; 60

        Exclusion Criteria:

          -  Blooddonation or transfusion during the last month

          -  Not willing to participate

          -  estimated GFR below 30ml/min

          -  type 1 diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesper N Bech, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regional Hospital Holstebro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erling B Perdersen, MD, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Regional Hospital Holstebro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Niels Peter Ekeløf, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regional Hospital Holstebro</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas N Jørgensen, MD</last_name>
    <phone>78436589</phone>
    <email>andrjr@rm.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Medical Research, Regional Hospital Holstebro</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2015</study_first_submitted>
  <study_first_submitted_qc>August 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2015</study_first_posted>
  <last_update_submitted>August 18, 2015</last_update_submitted>
  <last_update_submitted_qc>August 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Regional Hospital Holstebro</investigator_affiliation>
    <investigator_full_name>Erling Bjerregaard Pedersen</investigator_full_name>
    <investigator_title>Professor, MD</investigator_title>
  </responsible_party>
  <keyword>Vasoactive hormones</keyword>
  <keyword>bio markers</keyword>
  <keyword>salt regulation</keyword>
  <keyword>Renal variables</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasma-lyte 148</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

